Compare AbCellera Biologics Inc (ABCL) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Ferrari NV — how do they compare? AbCellera Biologics Inc trades at $10.35 (market cap $2.99B), while Ferrari NV trades at $409.9 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 24× AbCellera Biologics Inc's market cap, and Ferrari NV pays a 1.04% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | RACE | |
|---|---|---|
Market Cap | $2.99B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $504.09 |
52-Week Low | $2.78 | $314.63 |
Enterprise Value | $2.58B | $73.60B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
Ferrari (RACE) trades at $407.21, up 0.11% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, with 2025 revenue at $7.15 billion and net income margin of 22.25%, though valuation multiples like P/E of 37.93 are elevated.
The outlook remains positive given earnings beats, raised guidance, and analyst consensus favoring buys, but risks include high valuation sensitivity and economic cyclicality. Upside to the $462.67 price target depends on sustained premium demand execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
